Larimar Therapeutics (NASDAQ:LRMR) reported quarterly losses of $(0.30) per share which beat the analyst consensus estimate of $(0.39) by 23.08 percent. This is a 26.83 percent increase over losses of $(0.41) per share from the same period last year.